NASA’s Jet Propulsion Laboratory to Develop a Ventilator Specifically for COVID-19 Patients

News provided by

Independent Tech & news media Writer

May 19, 2020, 09:11 EST

Elkland, United States, May 19, 2020, 09:11 /Comserve / -- The Jet Propulsion Laboratory at NASA developed a ventilator device, known as VITAL (Ventilator Intervention Technology Accessible Locally) in just a time span of 37 days.

Image placeholder

The device received approval from the United States Food and Drug Administration as a ventilator for Emergency Use Authorization.

This device was developed as a result of the COVID-19 pandemic, for the patients affected by the disease. This is more advanced than the traditionally used ventilators in hospitals as the VITAL contains much less number of parts than normal ventilators. Further, it can be used for up to three to four months and the organization is offering its license for free manufacture of the device. The license to this has been applied for by more than a hundred manufacturers from all over the world, which will be selected later.

The ventilator developed by the JPL was designed to meet the high-pressure oxygen flow demand that was required by the COVID-19 patients as they suffer from Acute Respiratory Distress Syndrome. The cost of this is cheaper as the number of parts are reduced and in addition to this, the parts are also easily available in the United States. This would allow the mass production of these ventilators.

It was also kept in mind while developing VITAL, that the manufacturing of other traditionally used ventilators should not be hampered. Hence, the parts used in this device are separate from the ones used in other ventilators.

It is expected that the production of these ventilators in mass quantities would aid in the treatment of people affected by COVID-19 as the number of cases of this disease is predicted to increase further in the coming months. VITAL could be used to save a large number of lives in the United States. Once it is developed, it can be used for curing other pulmonary disorders as well.

Independent Tech & news media Writer

For more information, please contact:

Marlin Bode

Independent Tech & news media Writer
Tel: +1 814-302-1499

Related Links

Also from this source

New Prodigy Cloud System Announced by S2C Aimed At Next Generation SoC Prototyping

The world leader in FPGA-based prototyping solutions for accelerated SoC verification, S2C, announce

A Genetic Test to identify and diagnose Fragile X Syndrome receives FDA sanction for marketing for the first time

The U.S. FDA has accorded its sanction for marketing of the first test that could help identify and